Skip to content
Max Healthcare Institute logo

Max Healthcare Institute

MAXHEALTH NSE
₹1,081.00 +40.35 (+3.88%)
Market Cap
₹1,05,215 Cr
P/E
76.23
View as Markdown
MCP
Close 20 Nov 2026 ₹1,081.00 1Y −74.80 −6.47%
Start ₹1,155.80

Key Fundamentals

MidcapHealthcare ServicesHealthcare

Price-based figures as of · EPS basis: Consolidated · TTM

ROCE
14.70%
Debt to Equity
0.33
EPS (TTM)
₹14.18
Book Value
₹116.43
Market Cap
₹1,05,215 Cr
P/E (TTM)
76.23
P/B
9.28
ROE
14.70%
Dividend Yield
0.19%
EBITDA
₹2,406 Cr
52W High
₹1,185.40
52W Low
₹797.00
Day Range
₹1,050.05 – ₹1,090.00
Volume
95,31,767

Peer Comparison

Healthcare › Healthcare Services › Hospital

Max Healthcare Institute peer comparison
9,200.0059.001,32,28212.470.23%21.50%17.40%27,6302,337
1,081.0076.231,05,2159.280.20%14.70%14.70%9,1461,380
702.20101.7792,3666.010.00%6.72%8.30%12,370873
779.30110.7067,9298.720.41%11.30%11.60%6,508564
825.0059.9662,2845.940.13%11.20%13.40%9,9101,061
1,480.2064.3339,7989.200.03%15.20%17.40%5,053613
1,943.7046.2539,7227.940.24%20.50%15.50%10,273859
Median 7 companies1,081.0064.3367,9298.720.20%14.70%14.70%9,910873

Comparable companies in the same industry. Market cap, P/E and P/B use the latest price; other metrics are as reported in filings. A dash means the figure is not published for that company.

Tapetide Score

Data-driven rating, 0–100, as of . How it works →

Overall score

39 Weak

Data confidence 100/100

Category scores

Quality
51
Average
Returns, margins, earnings quality 22% weight
Valuation
29
Poor
Cheap vs sector & own history 24% weight
Growth
40
Weak
Sales & profit trajectory 9% weight
Financial Health
44
Weak
Solvency, leverage, coverage 9% weight
Momentum
20
Poor
Trend strength, vol-adjusted 12% weight
Ownership
46
Average
FII/DII/promoter flows 24% weight

The Tapetide Score is data analysis, not investment advice. Tapetide is not a SEBI-registered research analyst or investment adviser.

Key Insights

No strengths listed

Weaknesses

4
  • Stock is trading at 9.28 times its book value
  • Company has a low return on equity of 13.7% over last 3 years.
  • Company might be capitalizing the interest cost
  • Dividend payout has been low at 13.6% of profits over last 3 years

Technical Indicators

Technical signals: verdict and indicator counts
GroupSignalBearishNeutralBullish
OverallStrong Bullish5113
OscillatorsStrong Bearish513
Moving AveragesStrong Bullish0010

Key readings

RSI (14)
79.64
Bearish
MACD (12,26,9)
36.70
Bullish
SMA (50)
941.30
Bullish
SMA (200)
1,010.86
Bullish

As of

Analyst Rating

Based on 25 analysts
BUY80%

20 of 25 analysts rate Buy, 2 Hold, 3 Sell.

As of

BUY
20
80%
HOLD
2
8%
SELL
3
12%

Growth Rate

From the financial statements below. 5Y, 3Y: compound annual growth to Mar 2026; 1Y: fiscal year to Mar 2026 against Mar 2025; TTM: four quarters to Sep 2026 against Sep 2025.

Revenue

Revenue growth by window
5Y+27.27%
3Y+22.43%
1Y+19.14%
TTM+15.17%

Net profit

Net profit growth by window
5YTurned to profit
3Y+9.31%
1Y+34.01%
TTM+1.69%

Operating cash flow

Operating cash flow growth by window
5Y+69.13%
3Y+10.54%
1Y+13.56%
TTM—

TTM: Reported once a year, so there is no trailing-twelve-month figure.

Operating margin· change in pp

Operating margin growth by window
5Y+10.56 pp
3Y−0.41 pp
1Y+0.48 pp
TTM+0.26 pp

Revenue by year

Revenue by year, ₹ crore
Mar 2017₹1,608 Cr
Mar 2018₹1,729 Cr
Mar 2019₹1,691 Cr
Mar 2020₹1,059 Cr
Mar 2021₹2,508 Cr
Mar 2022₹3,937 Cr
Mar 2023₹4,563 Cr
Mar 2024₹5,406 Cr
Mar 2025₹7,028 Cr
Mar 2026₹8,373 Cr

Net profit by year

Net profit by year, ₹ crore
Mar 2017₹16.00 Cr
Mar 2018−₹25.00 Cr
Mar 2019₹0.00 Cr
Mar 2020₹59.00 Cr
Mar 2021−₹138 Cr
Mar 2022₹605 Cr
Mar 2023₹1,104 Cr
Mar 2024₹1,058 Cr
Mar 2025₹1,076 Cr
Mar 2026₹1,442 Cr

Analyst Forecasts

Forecast For
Dec 26 consensus · EBITDA
₹775 Cr +3.0% vs Sep 26
Reported High Mean Low

AI Analysis — Bull vs Bear

Figures as of 19 Nov 2026
AI opinion · based on fundamentals
Risk high

Max Healthcare Institute Ltd trades at ₹1,040.65 as of 2026-11-19 with a market cap of ₹1,01,288 crore, commanding a PE of 73.39x and a PB of 8.94x. The company has delivered 22% compounded sales growth over three years alongside a modest 13.42% ROE, while maintaining a relatively conservative debt-to-equity ratio of 0.32.

Bull Case 7
  • Strong revenue growth trajectory with compounded sales CAGR of 22% over 3 years and 27% over 5 years, reflecting consistent top-line expansion in the hospital business
  • Low leverage with a debt-to-equity ratio of just 0.32, providing financial flexibility for capacity expansion and acquisitions without excessive balance sheet risk
  • Healthy long-term stock price CAGR of 24% over 5 years and 20% over 3 years, indicating sustained investor confidence and wealth creation
  • Improving return on equity profile — ROE has trended upward from 11% on a 10-year basis to 14% over 5 years and 15% in the last year, suggesting improving capital efficiency
  • TTM revenue growth remains solid at 15% compounded sales growth, showing the business continues to scale even on a higher base
  • Compounded profit growth of 60% over 5 years demonstrates significant operating leverage and margin expansion over the medium term
  • Operating in the Indian private healthcare sector which benefits from structural tailwinds including rising insurance penetration, an aging demographic, and growing per-capita healthcare spend
Bear Case 7
  • Stock trades at 8.94 times book value, a steep premium that prices in substantial future growth and makes the stock vulnerable to de-rating
  • TTM profit growth has decelerated sharply to just 1%, a stark contrast to the 5-year compounded profit growth of 60%, raising questions about earnings momentum
  • Dividend payout has been low at 13.6% of profits over the last 3 years with a current yield of only 0.20%, offering negligible income return to shareholders
  • Three-year average ROE of approximately 13.7% is modest relative to the premium valuation, suggesting the market is pricing in far higher future returns on capital than currently delivered
  • The company may be capitalizing interest costs, which could overstate reported profitability by shifting financing expenses from the income statement to the balance sheet
  • Stock is down roughly 12% from its 52-week high of ₹1,185.40, and the 1-year stock CAGR of -11% indicates recent negative price momentum
  • Three-year compounded profit growth of only 10% against a 22% sales CAGR suggests margin compression or rising costs are absorbing a portion of revenue gains

This is AI-generated analysis, not financial advice. Do your own due diligence.

AI News Digest

22h ago

TL;DR: Max Healthcare delivered a solid Q2FY27 with 20% revenue growth and healthy EBITDA expansion, while GIC's stake increase to 5% underscores institutional conviction. No material headwinds emerged in the recent news cycle, and pending NCLT proceedings on Kalinga Hospital remain a watch item rather than a near-term risk. The operational and financial trend is firmly positive, with capacity expansion plans likely to sustain growth momentum into H2FY27.

Positives 3
  • Q2FY27 revenue up 20% YoY Nov 9

    Max Healthcare reported Q2FY27 revenue of ₹3,219 crore (up 20% YoY), operating EBITDA of ₹820 crore (up 18%), and PAT of ₹448 crore (up 10%).

  • GIC raises stake to 5% Nov 20

    GIC acquired 3,04,579 shares on Nov 18, raising its combined holding in Max Healthcare to 5.005%, signaling institutional confidence.

  • Investor forum participation Nov 13

    Max Healthcare presented its investor deck covering financials, capacity expansion, and growth strategy at the 29th CITIC CLSA India Forum on Nov 17 and participated in a Goldman Sachs conference on Nov 13.

Neutral 3
  • Large block trades on NSE Nov 17

    Two large trades were flagged on Nov 16-17: ~3.05 lakh shares at ₹1,023.70 (₹31.16 crore) and ~2.41 lakh shares at ₹975.20 (₹23.47 crore). Buyer/seller identities are unknown.

  • NCLT Kalinga hearing adjourned Oct 29

    The NCLT Cuttack Bench adjourned petitions against subsidiary Kalinga Hospital to Oct 30, 2026, citing lack of time.

  • PRSU scheme and CMD pay approved Oct 27

    Shareholders approved a new Performance Linked Restricted Stock Unit scheme for 2026 and remuneration for CMD Abhay Soi via postal ballot.

Quarterly Results

₹ Cr
MAXHEALTH quarterly results, ₹ crore
Particulars Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026
Sales
1,363
1,335
1,423
1,543
1,707
1,868
1,910
2,028
2,135
2,068
2,143
2,366
2,569
Expenses
976
949
1,041
1,156
1,257
1,369
1,398
1,505
1,560
1,529
1,536
1,768
1,858
Operating Profit
387
386
382
387
451
499
512
523
575
538
606
598
711
OPM %
28%
29%
27%
25%
26%
27%
27%
26%
27%
26%
28%
25%
28%
Other Income
45
46
45
35
41
33.3
47
37
33
45.38
48
41
40.9
Interest
9
11
21
24
34
52
55
55
54
60
67
71
73.84
Depreciation
58
61
70
77
84
98
101
104
108
111
123
132
138
Exceptional Items
—
—
—
—
—
−73.63
—
—
—
−48.24
—
—
—
PBT
366
360
336
321
374
309
402
400
446
365
465
436
541
Tax %
24%
20%
25%
26%
25%
23%
21%
23%
−10%
17%
26%
26%
23%
Net Profit
277
289
252
236
282
239
319
308
491
301
342
323
414
EPS (₹)
2.85
2.98
2.59
2.43
2.90
2.46
3.28
3.17
5.05
3.09
3.52
3.31
4.26
YoY Sales growth
20
17
17
20
25
40
34
31
25
11
12
17
20

Profit & Loss

₹ Cr
MAXHEALTH profit and loss, annual, ₹ crore
Particulars Mar 2015 (S)Mar 2016 (S)Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales
790
912
1,608
1,729
1,691
1,059
2,508
3,937
4,563
5,406
7,028
8,373
9,146
Expenses
768
890
1,467
1,616
1,535
965
2,101
2,986
3,322
3,913
5,180
6,131
6,691
Operating Profit
22
22
141
113
156
94
407
951
1,241
1,493
1,849
2,243
2,455
OPM %
2.8%
2.5%
9%
7%
9%
9%
16%
24%
27%
28%
26%
27%
27%
Other Income
33
35
59
65
56
48
−122
110
139
178
156
163
126
Interest
43
30
100
99
101
83
179
101
84
60
165
235
271
Depreciation
49
50
96
94
103
46
174
221
232
245
359
447
504
Exceptional Items
—
—
—
—
—
—
—
—
—
—
−73.63
−48.24
—
PBT
−38
−24
5
−15
8
13
−69
739
1,064
1,365
1,406
1,676
1,806
Tax %
0%
0%
−236%
65%
102%
−1%
67%
18%
−4%
23%
24%
14%
—
Net Profit
−38
−24
16
−25
0
59
−138
605
1,104
1,058
1,076
1,442
1,381
EPS (₹)
−0.78
−0.44
0.29
−0.47
−0.06
1.10
−1.42
6.24
11.37
10.88
11.07
14.82
14.18
Div. Payout %
0%
0%
0%
0%
0%
0%
0%
0%
9%
14%
14%
13%
—
Sales growth
—
16
—
8
−2
−37
137
57
16
18
30
19
15

Balance Sheet

₹ Cr
MAXHEALTH balance sheet, annual, ₹ crore
Particulars Mar 2015 (S)Mar 2016 (S)Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026Sep 2026
Equity Capital
489
533
537
537
537
537
966
970
971
972
972
973
973
Reserves
523
762
655
627
426
2,016
4,673
5,313
6,439
7,436
8,409
9,774
10,359
Borrowings
296
273
874
981
1,003
875
1,101
913
689
1,299
3,010
3,478
3,795
Other Liabilities
141
171
1,080
1,157
1,389
546
1,803
1,993
2,003
2,293
2,795
2,959
3,595
Total Liabilities
1,449
1,740
3,146
3,302
3,355
3,974
8,543
9,189
10,102
12,000
15,186
17,184
18,722
Fixed Assets
430
424
2,244
2,227
2,192
851
6,536
7,018
7,039
8,784
11,502
12,991
13,966
CWIP
15
6
46
38
87
28
27
151
252
553
901
593
805
Investments
451
840
0
0
1
2,182
1
1
1
2
3
5
5
Other Assets
554
469
856
1,036
1,075
913
1,980
2,020
2,810
2,661
2,781
3,595
3,946
Total Assets
1,449
1,740
3,146
3,302
3,355
3,974
8,543
9,189
10,102
12,000
15,186
17,184
18,722

Cash Flow

₹ Cr
MAXHEALTH cash flow, annual, ₹ crore
Particulars Mar 2015 (S)Mar 2016 (S)Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating
39
64
156
166
89
77
118
741
1,209
1,122
1,438
1,633
Investing
−200
−330
−104
−124
−17
−2,641
206
−764
−1,187
−1,253
−1,593
−1,688
Financing
176
251
−48
−48
−74
2,353
191
−294
−289
−264
−163
59
Net Cash Flow
15
−16
4
−6
−2
−210
516
−317
−266
−395
−318
4
Free Cash Flow
−15
42
41
100
−27
−13
1
192
877
342
500
165
CFO/EBITDA
223
338
135
166
75
89
15
89
110
93
95
89

Ratios

MAXHEALTH financial ratios, annual
Particulars Mar 2015 (S)Mar 2016 (S)Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days
67
48
53
59
78
33
53
36
27
31
36
42
Inventory Days
20
18
20
24
26
43
34
24
30
26
26
23
Days Payable
171
183
184
227
292
286
274
174
212
207
198
175
Cash Conversion Cycle
−85
−117
−111
−144
−188
−210
−187
−114
−155
−149
−136
−110
Working Capital Days
−15
−33
−12
−24
−152
−137
−44
−24
−46
−43
−46
−41
ROCE %
—
0%
—
4%
6%
4%
7%
12%
15%
16%
15%
15%

Insights

Beta

AI-extracted from concalls & annual reports · figures as reported, with sources

Log in to view Max Healthcare Institute insights

70 extracted metrics across FY17–FY27.

Shareholding Pattern

As of Sep 2026

  • FIIs 40.52%
  • DIIs 31.00%
  • Promoters 23.71%
  • Public 3.28%
  • Others 1.48%

No promoter shares pledged as of Sep 2026

Change since Jun 2026

Not shown for some quarters: Others. Not available separately for this quarter: the shareholding filing gives Public and Others as one figure, shown under Public, so Others is left blank rather than estimated.

Documents

Frequently Asked Questions about Max Healthcare Institute

What does Max Healthcare Institute Ltd do?
Max Healthcare Institute Limited is primarily engaged in the providing healthcare services through primary care clinics, multi-speciality hospitals / medical centres and super-speciality hospitals providing operation and management, medical services, clinical, radiology, pathology services and…
Where is Max Healthcare Institute Ltd (MAXHEALTH) listed?
Max Healthcare Institute Ltd trades as MAXHEALTH on the NSE and under code 543220 on the BSE.
Which sector does Max Healthcare Institute Ltd belong to?
Max Healthcare Institute Ltd is classified under the Healthcare sector, in the Healthcare Services industry.
What is the market capitalisation of Max Healthcare Institute Ltd?
Max Healthcare Institute Ltd has a market capitalisation of ₹1,05,215 Cr as of 20 Nov 2026, which places it in the Midcap band.
What is the PE ratio of Max Healthcare Institute Ltd?
Max Healthcare Institute Ltd trades at a PE ratio of 76.23 as of 20 Nov 2026, on earnings per share of ₹14.18, against a book value of ₹116.43 per share.
What is the 52-week high and low of Max Healthcare Institute Ltd?
Over the last 52 weeks Max Healthcare Institute Ltd has traded between ₹797 and ₹1,185.4 as of 20 Nov 2026.
Does Max Healthcare Institute Ltd pay dividends?
Max Healthcare Institute Ltd has a dividend yield of 0.19%.
What is the Return on Equity (ROE) of Max Healthcare Institute Ltd?
Max Healthcare Institute Ltd reported a return on equity of 14.70%. Its debt-to-equity ratio is 0.33.

Company Information

Max Healthcare Institute Limited is primarily engaged in the providing healthcare services through primary care clinics, multi-speciality hospitals / medical centres and super-speciality hospitals providing operation and management, medical services, clinical, radiology, pathology services and related healthcare services.

Listed 21 Aug 2020
Face Value ₹10
Shares Outstanding 97,33,10,251

For AI agents and developers

Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/MAXHEALTH.md for Max Healthcare Institute Ltd: dated key facts, then this page's sections in order: latest price, key fundamentals, peer comparison, the Tapetide Score, technical indicators, analyst ratings, growth rates, analyst forecasts, the AI analysis and news digest (labelled as AI-generated), financial statements, shareholding pattern, documents and the FAQ.

Append .md to any Tapetide URL for the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live, structured queries instead of documents, use our Indian stock market MCP server.

Explore More